Study shows combination stroke therapy safe and effective
The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found. Results from the study, known as the CLEAR-ER Stroke Trial, are published online in the journal Stroke: Journal of the American Heart Association. UC was the coordinating center for the trial, which included nine medical centers comprising 21 hospitals... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 1, 2013 Category: Consumer Health News Tags: Stroke Source Type: news
Study shows combination stroke therapy safe and effective
(University of Cincinnati Academic Health Center) The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati researchers has found. Results from the phase-2 clinical trial, known as the CLEAR-ER Stroke Trial, are published online in the journal Stroke: Journal of the American Heart Association. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 30, 2013 Category: Global & Universal Source Type: news
Adjunctive Use of Eptifibatide for Complication Management During Elective Neuroendovascular ProceduresAdjunctive Use of Eptifibatide for Complication Management During Elective Neuroendovascular Procedures
Is the antiplatelet agent eptifibatide an effective therapeutic strategy in the event of thromboembolism during elective neuroendovascular procedures? Journal of Neurointerventional Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Eptifibatide plus tPA looks promising for ischemic stroke
A phase 2 study has suggested that the GP IIb/IIIa blocker can be safely combined with a reduced dose of tPA, and there was a sufficient signal of efficacy to justify a phase 3 trial. (Source: theHeart.org)
Source: theHeart.org - February 15, 2013 Category: Cardiology Source Type: news
Eptifibatide Plus tPA Looks Promising for Ischemic StrokeEptifibatide Plus tPA Looks Promising for Ischemic Stroke
A phase 2 study has suggested that the glycoprotein IIb/IIIa blocker can be safely combined with a reduced dose of tPA, and there was a sufficient signal of efficacy to justify a phase 3 trial. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 14, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
